🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

647 results for “Les” Clear

  1. Jueyin granules

    Universal Integrated

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  2. KB304

    Krystal Biotech Netherlands B.V.

    Wrinkles in Decolletage

    phase 2 mab active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions

    phase 2 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun

    Philogen S.p.A.

    Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy

    phase 2 small molecule active

    1 trial

  5. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  6. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≤ 5cm or - multiple tumours (max 3 lesions ≤ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: • Serum AFP>100 ng/mL • Infiltrative form • Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  7. LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules

    Eisai Co.,

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  8. LENVIMA 4 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    advanced stage hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  9. LOMUSTINE , Odomzo 200 mg hard capsules, VINCRISTINE, CISPLATIN

    Ningbo Cancer Hospital

    Newly Diagnosed Medulloblastoma

    phase 2 small molecule active

    1 trial

  10. LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001

    Novartis Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  11. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 2 small molecule completed

    1 trial

  12. Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, IMBRUVICA 140 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 15 mg hard capsules, JNJ-54179060, Lenalidomide Accord 2.5 mg hard capsules, Ruxi

    Janssen-Cilag International N.V.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  13. Lifei Qingchang Granules

    The First People's Hospital of Lianyungang

    Bronchiectasis

    phase 2 small molecule active

    1 trial

  14. Liposorber LA-15 System

    Hospital Authority, Hong Kong

    Cholesterol Embolism

    phase 2 other active

    1 trial

  15. MB07811

    LIGAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  16. MD-0727

    IRONWOOD PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  17. MGL-3196 (resmetirom)

    Madrigal Pharmaceuticals EU Limited

    Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  18. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis

    phase 2 small molecule completed

    1 trial

  19. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Cholestatic Liver Disease

    phase 2 small molecule completed

    1 trial

  20. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule active

    1 trial

  21. Mektovi 15 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)

    phase 2 small molecule active

    1 trial

  22. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  23. Mosunetuzumab, Mosunetuzumab, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Mosunetuzumab, Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Follicular Lymphoma (FL)

    phase 2 small molecule active

    1 trial

  24. Mosunetuzumab, Mosunetuzumab, TOCILIZUMAB , BRUKINSA 80 mg hard capsules

    Fondazione Telethon ETS

    Follicular lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources